Phase 3 Clinical Trial of NAC Launched for RP Patients
Listen now
Description
The drug is thought to work independent of the mutated gene causing RP.
More Episodes
Peter Wallsten, a veteran newspaper journalist and head of investigative reporting at The Washington Post, talks to host Ben Shaberman about his evolving career as a reporter and editor and the impact that Stargardt disease has had on his journey and ambitions. Peter also reflects on recently...
Published 05/24/24
Published 05/24/24
The emerging treatment is designed to work for people with RP and other conditions regardless of the gene mutation causing disease
Published 05/22/24